Vertex: Q3 2013 Results (Vertex) - Nov 2, 2013 - Anticipated results from 100mg and 200mg arms of P2 12-week combination therapy trial (VX-135+daclatasvir) in G1 hep C infected patients in early 2014; Anticipated presentation of EU data from P2 12-week combination therapy trial (VX-135+daclatasvir) in G1 hep C infected patients at AASLD (Nov 03, 2013)
Anticipated P2 data • Hepatitis C Virus
|